MD vs NKTR vs THC vs HALO vs HCA

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Pediatrix Medical Group, Inc. (MD) offers the better valuation at 11. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pediatrix Medical Group, Inc.

(MD) is the cheapest at 11. 8x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.

4%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: HALO returned +570. 7% versus MD's -67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HCA Healthcare, Inc.

(HCA) is the lower-risk stock at 0. 29β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 546% more volatile than HCA relative to the S&P 500. On balance sheet safety, Pediatrix Medical Group, Inc. (MD) carries a lower debt/equity ratio of 76% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Pediatrix Medical Group, Inc. grew EPS 263. 0% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 1x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 59. 3% to $132. 83.

In this comparison, HCA (0.

7% yield) pays a dividend. MD, NKTR, THC, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, HCA Healthcare, Inc.

(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +450. 5%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MD is a small-cap deep-value stock; NKTR is a small-cap quality compounder stock; THC is a mid-cap deep-value stock; HALO is a small-cap high-growth stock; HCA is a mid-cap deep-value stock. HCA pays a dividend while MD, NKTR, THC, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.